CYTK News 9.52 Cytokinetics Inc (CYTK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytokinetics Inc (CYTK) 9.52 $CYTK

Equities Updates on Top Gainers -- Research on E-Commerce China Dangdang, Neuralstem, Cytokinetics, and Nu Skin Enterprises
PR Newswire - Thu Apr 10, 12:30PM CDT
The US markets saw a positive sentiment on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 edging 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including E-Commerce China Dangdang Inc. (NYSE: DANG), Neuralstem Inc. (NYSE: CUR), Cytokinetics Inc. (NASDAQ: CYTK) and Nu Skin Enterprises Inc. (NYSE: NUS). Free technical research on DANG, CUR, CYTK and NUS can be downloaded upon signing up at:

Uptrend Call Working As Cytokinetics Stock Rises 11.9% (CYTK)
Comtex SmarTrend(R) - Thu Apr 10, 9:27AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 months, Cytokinetics has returned 11.90% as of today's recent price of $9.78.

Nasdaq stocks posting largest percentage increases
AP - Wed Apr 09, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.

Cytokinetics to Present at the 13th Annual Needham Healthcare Conference
Thomson Reuters ONE - Tue Apr 01, 3:06PM CDT
South San Francisco, CA, April 1, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 1:40 PM Eastern Daylight Time at the Westin Grand Central Hotel in New York, New York.

Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC-HF
Thomson Reuters ONE - Fri Mar 28, 6:31AM CDT
Commencement of Next Stage in International Phase II Clinical Trial of Oral Formulation of Omecamtiv Mecarbil in Patients with Heart Failure

Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Thomson Reuters ONE - Thu Mar 27, 6:31AM CDT
Commencement of Study Triggers Milestone Payment from Astellas

Cytokinetics Up 15.0% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Wed Mar 19, 11:11AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 1 month, Cytokinetics has returned 14.99% as of today's recent price of $10.05.

Cytokinetics Shares Up 24.0% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Wed Mar 05, 9:27AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 3 weeks, Cytokinetics has returned 24.03% as of today's recent price of $10.84.

Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.

Cytokinetics to Present at Upcoming Healthcare Conferences
Thomson Reuters ONE - Fri Feb 28, 3:01PM CST
South San Francisco, CA, February 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences:

Multiple Insiders of Cytokinetics, Incorporated (CYTK)-NasdaqCM bought Shares of CYTK
M2 - Fri Feb 28, 8:34AM CST
Reported by InsiderCow.com at 2014-02-27 15:33:52 ET

Shares of CYTK Up 15.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:28AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 weeks, Cytokinetics has returned 15.10% as of today's recent price of $10.06.

Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
Thomson Reuters ONE - Tue Feb 25, 3:00PM CST


Trade-Ideas: Cytokinetics (CYTK) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Feb 21, 8:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a "dead cat bounce" (down big yesterday but up big today) candidate

Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock
Thomson Reuters ONE - Thu Feb 20, 7:56AM CST
South San Francisco, CA, February 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share. Cytokinetics anticipates its aggregate gross proceeds will be approximately $35.0 million before deducting the underwriting discount and estimated offering expenses payable by Cytokinetics. In addition, Cytokinetics has granted the underwriters a 30 day option to purchase up to an additional 656,250 shares of common stock under the same terms and conditions solely to cover over-allotments, if any. All of the shares in the offering are to be sold by Cytokinetics. The offering is expected to close on or about February 25, 2014, subject to the satisfaction of customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 64

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 73

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 71

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 56

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 47

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading

Top 5 Most Recently Viewed Articles

Happy Day Brands and Sysco's Powerful Partnership for Change

Updated Category News Views 213

Happy Day Brands and Sysco Unite to Fight Hunger Happy Day Brands is stepping into the spotlight with an exciting partnership alongside Sysco that aims to nourish communities during a time when support is crucial. This collaboration is set to engage multiple states in a significant act of community service. Together, they will package over one million servings of...

Continue Reading
Upcoming Market Trends: The Influence of Trade Tensions

Updated Category News Views 245

Market Dynamics Shaped by Trade Tensions As we enter a new trading week, the economic landscape is painted with the resurgence of trade tensions. The discussions around tariffs, notably involving major economies, signal a return to aggressive trade policies that could influence market behavior. Understanding the Impact of Tariffs The reintroduction of tariffs has stirred...

Continue Reading
Carma HoldCo Invests in Mr. Charlie's for Plant-Based Growth

Updated Category News Views 150

Carma HoldCo Expands into Plant-Based Fast Food Market Carma HoldCo, renowned for its innovative brand portfolio, is making a significant leap into the plant-based quick-service restaurant (QSR) sector through a strategic investment in Mr. Charlie's Told Me So (TMS). This exciting partnership underlines the growing trend of health-conscious dining, particularly as...

Continue Reading
Advent Technologies to Showcase Innovative Maritime Solutions

Updated Category News Views 179

Advent Technologies Takes Center Stage at IEA Conference Advent Technologies Holdings, Inc. (NASDAQ: ADN) has announced that Dr. Emory De Castro, the Chief Technology Officer, will participate in the upcoming International Energy Agency (IEA) conference, set to occur in a prominent location soon. This event focuses on fuel cell applications within the maritime industry....

Continue Reading
Growing Demand in Polarized Sunglasses Market

Updated Category News Views 23

Polarized Sunglasses Gaining Traction Get this—polarized sunglasses are catching eyes like a bandwagon with NOS. Consumer365 just threw a nod at EZContacts for their impressive lineup of designer shades that promise to cut the glare while keeping those retinas comfy from the sun's death rays. Understanding the Hype Around Polarized Lenses Look, if you're fed up with...

Continue Reading